ARF1

Across TCGA pan-cancer cohorts, ARF1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARF1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARF1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARF1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where ARF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.675	0.366	<.001	36	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.433	.005	34	view →
HNSC	DFS	Quartile	IV	0.878	0.510	.003	8	view →
LUAD	DFS	Tertile	II,III,IV	0.307	0.748	.016	5	view →
CCRCC	OS	Median	All	1.000	0.906	.021	4	view →
GBM	DFS	Tertile	All	0.255	0.419	.033	4	view →
LSCC	DFS	Median	III,IV	0.501	0.875	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARF1–PDAC (OS)

Open the PDAC breakdown →